Daniel Centanni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Centanni has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Birgitte Klug Albertsen
Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark
1 shared publication Goda Elizabeta Vaitkeviciene
Vilnius University Children’s Hospital, Vilnius, Lithuania
1 shared publicationHelene Hallböök
Dept Of Medical Sciences, Haematology, Uppsala University, Uppsala, Sweden
1 shared publicationHilde Skuterud Wik
Department of Haematology, Oslo University Hospital, Oslo, Norway
1 shared publicationInga Maria Johannsdottir
Department of Paediatric Haematology and Oncology, Oslo University Hospital, Oslo, Norway
1 shared publicationJohan Malmros
Astrid Lindgren Children’s Hospital, Karolinska University Hospital and Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 29 January 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 712-719
Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.
- 29 January 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 712-719
Open AccessIncrease in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies, silent inactivation, or allergy-like responses. We hypothesized that even moderate increases in asparaginase clearance are related to later inactivation. We therefore explored mandatory monitoring of asparaginase enzyme activity (AEA) in patients with ALL aged 1–45 years treated according to the ALLTogether pilot protocol in the Nordic and Baltic countries to relate mean AEA to inactivation, to build a pharmacokinetic model to better characterize the pharmacokinetics of peg-asparaginase and assess whether an increased clearance relates to subsequent inactivation. The study analyzed 1631 real-time AEA samples from 253 patients, identifying inactivation in 18.2% of the patients. This inactivation presented as mild allergy (28.3%), severe allergy (50.0%), or silent inactivation (21.7%). A pharmacokinetic transit compartment model was used to describe AEA-time profiles, revealing that 93% of patients with inactivation exhibited prior increased clearance, whereas 86% of patients without hypersensitivity maintained stable clearance throughout asparaginase treatment. These findings enable prediction of inactivation and options for either dose increments or a shift to alternative asparaginase formulations to optimize ALL treatment strategies.